-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Vaxart, Inc. (NASDAQ:VXRT) Stake Increased by Tower Research Capital LLC TRC
Vaxart, Inc. (NASDAQ:VXRT) Stake Increased by Tower Research Capital LLC TRC
Tower Research Capital LLC TRC lifted its stake in Vaxart, Inc. (NASDAQ:VXRT – Get Rating) by 147.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,073 shares of the biotechnology company's stock after acquiring an additional 51,953 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Vaxart worth $190,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of VXRT. State Street Corp increased its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company's stock worth $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. Barclays PLC increased its position in Vaxart by 6,969.5% during the third quarter. Barclays PLC now owns 656,117 shares of the biotechnology company's stock worth $1,430,000 after buying an additional 646,836 shares during the last quarter. UBS Group AG increased its position in Vaxart by 34.6% during the first quarter. UBS Group AG now owns 836,815 shares of the biotechnology company's stock worth $4,217,000 after buying an additional 214,901 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Vaxart by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 434,678 shares of the biotechnology company's stock worth $2,191,000 after buying an additional 214,197 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Vaxart by 28.7% during the first quarter. Bank of America Corp DE now owns 631,861 shares of the biotechnology company's stock worth $3,185,000 after buying an additional 140,833 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.
Get Vaxart alerts:Analysts Set New Price Targets
Separately, B. Riley lowered their target price on shares of Vaxart from $6.00 to $1.50 and set a "neutral" rating on the stock in a research report on Monday, December 19th.
Vaxart Price Performance
Vaxart stock opened at $0.81 on Tuesday. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.82. The company's fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.57. Vaxart, Inc. has a one year low of $0.73 and a one year high of $5.43.
Vaxart Profile
(Get Rating)
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.
Featured Articles
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT – Get Rating).
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
Tower Research Capital LLC TRC lifted its stake in Vaxart, Inc. (NASDAQ:VXRT – Get Rating) by 147.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,073 shares of the biotechnology company's stock after acquiring an additional 51,953 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Vaxart worth $190,000 as of its most recent filing with the Securities and Exchange Commission.
根據最近與證券交易委員會的披露,塔研究資本有限責任公司 TRC 在 Vaxart 公司(NASDAQ:VXRT-獲得評級)在第三季度取消了 147.9% 的股份。該基金在本季度額外收購 51,953 股後,擁有該生物技術公司股票的 87,073 股。塔研究資本有限責任公司 TRC 擁有約 0.07% 的 Vaxart 價值 190,000 美元作為其最近向證券交易委員會提交的文件。
A number of other hedge funds have also modified their holdings of VXRT. State Street Corp increased its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company's stock worth $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. Barclays PLC increased its position in Vaxart by 6,969.5% during the third quarter. Barclays PLC now owns 656,117 shares of the biotechnology company's stock worth $1,430,000 after buying an additional 646,836 shares during the last quarter. UBS Group AG increased its position in Vaxart by 34.6% during the first quarter. UBS Group AG now owns 836,815 shares of the biotechnology company's stock worth $4,217,000 after buying an additional 214,901 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Vaxart by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 434,678 shares of the biotechnology company's stock worth $2,191,000 after buying an additional 214,197 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Vaxart by 28.7% during the first quarter. Bank of America Corp DE now owns 631,861 shares of the biotechnology company's stock worth $3,185,000 after buying an additional 140,833 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.
許多其他對沖基金也修改了其對 VXRT 的持有量。州街公司在第一季度增加了 23.9% 的 Vaxart 股份的股份。州街公司現在擁有該生物技術公司股票的 13,860,974 股價值 69,859,000 美元,在上一季度額外收購 2,673,332 股股票後。巴克萊 PLC 在第三季度增加了 6,969.5% 在瓦哈特的地位。在上一季度額外購買 646,836 股股票後,巴克萊有限公司現在擁有該生物技術公司股票的 656,117 股價值 1,430,000 美元。瑞銀集團在第一季度增加了 34.6% 在瓦哈特的地位。瑞銀集團股份有限公司在上一季度額外購入 214,901 股股票後,擁有該生物科技公司股票價值 4,217,000 元的 836,815 股股份。高盛集團在第一季度增加了 97.1% 在 Vaxart 的地位。高盛集團股份有限公司現在擁有該生物技術公司股票的 434,678 股,價值 2,191,000 美元,在上一季度額外購買了 214,197 股股票後。最後,美國銀行公司 DE 在第一季度增加了 28.7% 在瓦哈特的地位。美國銀行 DE 現在擁有該生物技術公司股票的 631,861 股,價值 3,185,000 美元,在上一季度額外購買了 140,833 股。38.66% 的股票由機構投資者和對沖基金擁有。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, B. Riley lowered their target price on shares of Vaxart from $6.00 to $1.50 and set a "neutral" rating on the stock in a research report on Monday, December 19th.
另外,萊利在 12 月 19 日(星期一)的一份研究報告中,萊利將 Vaxart 股票的目標價格從 6.00 美元降至 1.50 美元,並在該研究報告中設定了該股票的「中性」評級。
Vaxart Price Performance
瓦沙特價格性能
Vaxart stock opened at $0.81 on Tuesday. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.82. The company's fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.57. Vaxart, Inc. has a one year low of $0.73 and a one year high of $5.43.
華沙股票週二以 0.81 美元開盤。該公司的市值為 105.79 億美元,價格與收益比為 -0.97,測試版為 0.82。該公司的五十天移動平均價為 0.99 美元,其 200 日移動平均價格為 1.57 美元。瓦沙特公司擁有一年低點 0.73 美元,一年新高為 5.43 美元。
Vaxart Profile
瓦沙特個人檔案
(Get Rating)
(取得評分)
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.
Vaxart, Inc. 是一家臨床階段的生物技術公司,該公司根據其向量-輔助抗原標準化技術(VAAST)口服疫苗平台從事口服重組疫苗的開發。其研究性疫苗使用室溫穩定的片劑進行治療,而不是通過注射。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
- 獲取有關瓦沙特(VXRT)的股票新聞網研究報告的免費副本
- 去錢所在的地方。這是 3 個要購買的頂級銀行股息股票
- 馬倫汽車股票的另一種催化劑
- 太陽能技術服務;Nextracker 應該在您的雷達上
- 隨著對鋰的需求飆升,美國鋰是安全的賭注嗎
- 高木物業,優質房地產折扣
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT – Get Rating).
想看看還有哪些對沖基金持有 VXRT? 訪問控股通道以獲取瓦哈特公司(納斯達克:VXRT — 獲得評分)的最新 13 樓文件和內幕交易。
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
接收瓦哈特日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Vaxart 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧